PIK3CB and prostate cancer: Pathways such as the PI3K/AKT/mTOR pathway’s inhibitor with limited response may be further linked to the activation of the compensatory cascade of mitogen-activated protein kinase (MAPK), and the relevant research using preclinical models of prostate cancer demonstrates that the cancer is increasing enormously after blocking both channels together (89).